All AbMole products are for research use only, cannot be used for human consumption.
For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.
(±)-ML 209 (compound 4n), a diphenylpropanamide, is a retinoic acid-related orphan receptor RORγ antagonist with an IC50 of 1.1 μM. (±)-ML 209 inhibits RORγt transcriptional activity with an IC50 of 300 nM in HEK293t cells. (±)-ML 209 inhibits the transcriptional activity of RORγt, but not RORα in cells. (±)-ML 209 selectively inhibits murine Th17 cell differentiation without affecting the differentiation of naïve CD4+ T cells into other lineages, including Th1 and regulatory T cells.
Molecular Weight | 441.52 |
Formula | C25H31NO6 |
CAS Number | 1334526-14-5 |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
[4] Karin English, et al. J Hazard Mater. BDE-209 in the Australian Environment: Desktop review
Related ROR Products |
---|
ASN06917370
ASN06917370 is a former orphan receptor GPR17 ligand for the study of neurodegenerative diseases. |
JTE-151
JTE-151 is a RORγ inhibitor that suppresses overactive immune responses by inhibiting RORγ associated with Th17 cell activation.JTE-151 can be used in studies related to autoimmune diseases. |
SAR-441169
SAR-441169 is a RORγt inverse agonist that can be used in studies related to psoriasis. |
GRC-39815
GRC-39815 is a RORγt inverse agonist that can be used in studies related to chronic obstructive pulmonary disease. |
RORγ antagonist 1
RORγ antagonist 1, a potent betulinic acid derivative, is an antagonist of RORγ (KD=0.18 μM). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.